Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Atopic Dermatitis Control on Biologic Persists Over 3 Years
AMSTERDAM — For patients with atopic dermatitis (AD) who responded to the anti-interleukin (IL)-13 monoclonal antibody lebrikizumab in the pivotal trials, the level of response, including 90% skin clearance, has generally remained unchanged among those followed up for an additional…
English